SENATE BILL NO. 191

1

BY SENATORS CLOUD, BARROW, BERNARD, BOUDREAUX, CONNICK, CORTEZ, FIELDS, FOIL, HENSGENS, JACKSON, LAMBERT, MCMATH, MILLIGAN, FRED MILLS, ROBERT MILLS, PEACOCK, PETERSON, PRICE, SMITH, TALBOT AND WHITE AND REPRESENTATIVES BROWN, BUTLER, CARRIER, WILFORD CARTER, DESHOTEL, EDMONDS, HARRIS, HORTON, MIKE JOHNSON, STAGNI, THOMPSON, WILLARD AND WRIGHT

Prefiled pursuant to Article III, Section 2(A)(4)(b)(i) of the Constitution of Louisiana.

AN ACT

2	To enact Subpart A-3 of Part III of Chapter 4 of Title 22 of the Louisiana Revised Statutes
3	of 1950, comprised of R.S. 22:1020.51 through 1020.53, relative to
4	provider-administered drugs; to provide for legislative intent; to provide for
5	definitions; to provide for access; to provide for payment to participating health care
6	providers; to provide with respect to penalties; and to provide for related matters.
7	Be it enacted by the Legislature of Louisiana:
8	Section 1. Subpart A-3 of Part III of Chapter 4 of Title 22 of the Louisiana Revised
9	Statutes of 1950, comprised of R.S. 22:1020.51 through 1020.53, is hereby enacted to read
10	as follows:
11	SUBPART A-3. PROTECTING PATIENT ACCESS TO
12	PHYSICIAN-ADMINISTERED MEDICATIONS
13	§1020.51. Purpose and intent
14	The purpose and intent of this Part is to ensure patient access to
15	physician-administered drugs and related services furnished to persons covered
16	under a health insurance contract. This Part shall ensure that health insurance

Page 1 of 4

Coding: Words which are struck through are deletions from existing law; words in **boldface type and underscored** are additions.

**SB NO. 191 ENROLLED** 

1	issuers do not interfere with patients' freedom of choice with respect to
2	providers furnishing physician-administered drugs and ensure that patients
3	receive safe and effective drug therapies.
4	<u>§1020.52. Definitions</u>
5	For purposes of this Part, the following words shall have the following
6	meanings:
7	(1) "Covered person" shall have the same meaning as provided in R.S.
8	<u>22:1019.1.</u>
9	(2) "Health insurance issuer" shall have the same meaning as provided
10	in R.S. 22:1019.1.
11	(3) "Participating provider" shall have the same meaning as provided
12	in R.S. 22:1019.1. For purposes of this Subpart, "participating provider" shall
13	include any clinic, hospital outpatient department, or pharmacy under the
14	common ownership or control of the participating provider.
15	(4) "Physician-administered drug" means any prescription drug, as
16	defined in R.S. 22:1060.1, other than a vaccine, that requires administration by
17	a provider and is not approved as a self-administered drug.
18	§1020.53. Physician-administered drugs; access; payment
19	A.(1) A health insurance issuer, pharmacy benefit manager, or their
20	agent shall not refuse to authorize, approve, or pay a participating provider for
21	providing covered physician-administered drugs and related services to covered
22	persons. A health insurance issuer shall not condition, deny, restrict, refuse to
23	authorize or approve, or reduce payment to a participating provider for a
24	physician-administered drug when all criteria for medical necessity are met,
25	because the participating provider obtains physician-administered drugs from
26	a pharmacy that is not a participating provider in the health insurance issuer's
27	network. The drug supplied shall meet the supply chain security controls and
28	chain of distribution set by the federal Drug Supply Chain Security Act,
29	Pub. L. 113-54, as amended. The payment shall be at the rate set forth in the

health insurance issuer's agreement with the participating provider applicable

30

**SB NO. 191 ENROLLED** 

1	to such drugs, or if no such rate is included in the agreement, then at the
2	wholesale acquisition cost. A health insurance issuer, pharmacy benefit
3	manager, or their agent, shall not require a covered person to pay an additional
4	fee, or any other increased cost-sharing amount in addition to applicable cost-
5	sharing amounts payable by the covered person as designated within the benefit
6	plan to obtain the physician-administered drug when provided by a
7	participating provider. However, nothing in this Subpart shall prohibit a health
8	insurance issuer or its agent from establishing differing copayments or other
9	cost-sharing amounts within the benefit plan for covered persons who acquire
10	physician-administered drugs from other providers. Nothing in this Subpart
11	shall prohibit a health insurance issuer or its agent from refusing to authorize
12	or approve, or from denying coverage of a physician-administered drug based
13	upon failure to satisfy medical necessity criteria. For purposes of this Section,
14	the location of receiving the physician-administered drug shall not be included
15	in the medical necessity criteria.
15 16	in the medical necessity criteria.  (2) Nothing in this Section shall prohibit a health insurance issuer from
16	(2) Nothing in this Section shall prohibit a health insurance issuer from
16 17	(2) Nothing in this Section shall prohibit a health insurance issuer from establishing specialty care centers of excellence based on nationally established,
16 17 18	(2) Nothing in this Section shall prohibit a health insurance issuer from establishing specialty care centers of excellence based on nationally established, objective quality measures, to be utilized by covered persons focused on specific
16 17 18 19	(2) Nothing in this Section shall prohibit a health insurance issuer from establishing specialty care centers of excellence based on nationally established, objective quality measures, to be utilized by covered persons focused on specific drugs or types of drugs to impact the safety, quality, affordability, and expertise
16 17 18 19 20	(2) Nothing in this Section shall prohibit a health insurance issuer from establishing specialty care centers of excellence based on nationally established, objective quality measures, to be utilized by covered persons focused on specific drugs or types of drugs to impact the safety, quality, affordability, and expertise of treatment.
16 17 18 19 20 21	(2) Nothing in this Section shall prohibit a health insurance issuer from establishing specialty care centers of excellence based on nationally established, objective quality measures, to be utilized by covered persons focused on specific drugs or types of drugs to impact the safety, quality, affordability, and expertise of treatment.  B. The commission of any act prohibited by this Part shall be considered
16 17 18 19 20 21 22	(2) Nothing in this Section shall prohibit a health insurance issuer from establishing specialty care centers of excellence based on nationally established, objective quality measures, to be utilized by covered persons focused on specific drugs or types of drugs to impact the safety, quality, affordability, and expertise of treatment.  B. The commission of any act prohibited by this Part shall be considered an unfair method of competition and unfair practice or act which shall subject
16 17 18 19 20 21 22 23	(2) Nothing in this Section shall prohibit a health insurance issuer from establishing specialty care centers of excellence based on nationally established, objective quality measures, to be utilized by covered persons focused on specific drugs or types of drugs to impact the safety, quality, affordability, and expertise of treatment.  B. The commission of any act prohibited by this Part shall be considered an unfair method of competition and unfair practice or act which shall subject the violator to any and all actions, including investigative demands, private
16 17 18 19 20 21 22 23 24	(2) Nothing in this Section shall prohibit a health insurance issuer from establishing specialty care centers of excellence based on nationally established, objective quality measures, to be utilized by covered persons focused on specific drugs or types of drugs to impact the safety, quality, affordability, and expertise of treatment.  B. The commission of any act prohibited by this Part shall be considered an unfair method of competition and unfair practice or act which shall subject the violator to any and all actions, including investigative demands, private actions, remedies, and penalties, provided for in the Unfair Trade Practices and
16 17 18 19 20 21 22 23 24 25	(2) Nothing in this Section shall prohibit a health insurance issuer from establishing specialty care centers of excellence based on nationally established, objective quality measures, to be utilized by covered persons focused on specific drugs or types of drugs to impact the safety, quality, affordability, and expertise of treatment.  B. The commission of any act prohibited by this Part shall be considered an unfair method of competition and unfair practice or act which shall subject the violator to any and all actions, including investigative demands, private actions, remedies, and penalties, provided for in the Unfair Trade Practices and Consumer Protection Law.

29

30

signed by the governor, upon expiration of the time for bills to become law without signature

by the governor, as provided by Article III, Section 18 of the Constitution of Louisiana. If

vetoed by the governor and subsequently approved by the legislature, this Act shall become
effective on the day following such approval.

PRESIDENT OF THE SENATE

SPEAKER OF THE HOUSE OF REPRESENTATIVES

GOVERNOR OF THE STATE OF LOUISIANA

APPROVED: \_\_\_\_\_\_

**ENROLLED** 

SB NO. 191